934342-31-1

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 1-Boc-3-fluoropiperidine-3-carboxylate is used as a key building block for the synthesis of various pharmaceuticals. Its unique structure and functional groups make it a valuable component in the development of new drugs and biologically active compounds.
Used in Organic Chemistry Research:
In the field of organic chemistry, Methyl 1-Boc-3-fluoropiperidine-3-carboxylate serves as an important intermediate for the synthesis of complex organic molecules. Its versatility and reactivity contribute to the advancement of organic chemistry and the discovery of novel chemical entities with potential applications in various industries.

Upstream product

• 934342-39-9 1-(tert-butoxycarbonyl)-3-fluoropiperidine-3-carboxylic acid 
• 74-88-4 methyl iodide 
• 133745-75-2 N-fluorobis(benzenesulfon)imide 
• 148763-41-1 1-(tert-butyl) 3-methyl piperidine-1,3-dicarboxylate 

Downstream Products

• 934342-39-9 1-(tert-butoxycarbonyl)-3-fluoropiperidine-3-carboxylic acid 

Relevant academic research and scientific papers

CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30

The present invention relates to a class of cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction. (I)

PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES

The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES

The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.

PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention provides a compound of Formula (I) and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.

HETEROARYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor